Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.

Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.

Eur J Med Chem. 2017 Jun 23;138:246-254

Authors: Song XD, Kong X, He SF, Chen JX, Sun J, Chen BB, Zhao JW, Mao ZW

Abstract
Guanidinium-functionalized molecules are commonly studied for their use as pharmaceutically active compounds and drugs carriers. Herein, four cyclometalated iridium(III) complexes containing guanidinium ligands have been synthesized and characterized as potential anticancer agents. These complexes exhibit moderate antitumor activity in HeLa, MCF-7, HepG2, CNE-2, and A549 human tumor cells. Interestingly, all complexes showed higher cytotoxicity than cisplatin against a cisplatin-resistant cell line A549R, and less cytotoxicity on the nontumorigenic LO2 cells. Intracellular distribution studies suggest that these complexes are selectively localized in the mitochondria. Mechanism studies indicate that these complexes arrested the cell cycle in the G0/G1 phase and can influence mitochondrial integrity, inducing cancer cell death through reactive oxygen species (ROS)-dependent pathways.

PMID: 28668477 [PubMed - as supplied by publisher]

http://ift.tt/2t8J3cy